Dr. Hulme joined Aeovian in January 2020 as CEO, President and Board Member, bringing with her 30 years of experience in drug development and commercialization.  Prior to this, she was the Chief Operating Officer, Head of Research and Development and Board member at Sophiris BIO, establishing the company’s California operations and leading the Topsalysin program from IND to Phase 3 in BPH and prostate cancer.

​

Prior to joining Sophiris, Dr. Hulme was the Executive Vice President and Head of Global Development at Elan Corporation plc. She directed many of its key programs including the approval and commercialization of Natalizumab, Tysabri®, for Multiple Sclerosis and Crohn’s disease, a first in kind, multi-billion dollar treatment currently commercialized by Biogen. In addition, she led the Phase 3 development of Elan’s Alzheimer’s Immunotherapy Programs resulting in a strategic investment by Johnson & Johnson of approximately $ 1.5 billion (transaction value).

​

Before Elan, Dr. Hulme held several positions in clinical research at Glaxo Wellcome Pharmaceuticals and was Lecturer in cell biology at Luton University. Dr. Hulme holds a first-class honors Degree in Cell Biology from University of  Bedfordshire  and a Ph.D. from Cranfield Institute of Technology.